• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Joergs friends and opposers


<



So first thing, NIBR to report into DE, make Fishman accountable for something, he is not Dean of Novartis Cambridge University, he takes an inflated salary from a "for profit company" and it's time he and the board smelt the coffee.
Proven experience should be a requirement, no more NIBR puppets promoted into jobs that they are clearly incapable of doing. Joerg, he could run Development better than the current load of muppets in his coffee break! TW cannot control a child's pocket money let alone a Development function of a major pharma company, Joerg must see that! He must have someone line up to take over.....at least I hope so, otherwise we are all doomed, Mark & Tim, Laurel & Hardy would have more idea.
 




Keep in mind that when MF took the job it was only accepted if he reported to Vasella directly, not to JR who was COO at the time and had 20+ years of R & D experience in the company. Now let's see if JR is still holding a grudge.